Genzyme Corp. (Nasdaq: GENZ) announced the U.S. launch of the phosphate binder Renvela® (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to secure additional approvals for the product. Genzyme has submitted a marketing authorization application to the European Medicines Agency seeking approval of Renvela for the control of serum phosphorus in chronic kidney disease patients regardless of whether they are on dialysis. This application, which includes both tablet and powder formulations, must be validated before it will be accepted for review.
Discuss Add this link to... Bury
Discuss Add this link to... Bury
Comments